Oneness Biotech announced promising progress on its new nucleic acid weight-loss drug SNS851 during an online investor conference held yesterday (28). The company stated that, compared with currently best-selling GLP-1 weight-loss drugs, combining SNS851 with GLP-1 can further boost weight-loss efficacy by 40%. Moreover, the rebound rate after discontinuation is only half that of GLP-1 alone, representing the best preclinical results published globally to date for weight-loss drugs.
Oneness Biotech plans to launch a Phase I clinical trial in Australia in the fourth quarter of this year, while simultaneously engaging in partnership discussions with international pharmaceutical companies to advance global commercialization.
Following the successful Phase II trial of its first-in-class COVID-19 drug SNS812, Oneness Biotech has invested heavily in nucleic acid drug development over the past two years. The latest data from SNS851 has once again demonstrated impressive results, with preclinical efficacy significantly surpassing that of international peers. The company intends to prioritize the accelerated development of SNS851. In line with resource allocation considerations, it has decided to halt the development of its Phase I liver cancer drug, redirecting resources toward projects with greater commercial potential.
Oneness Biotech General Manager Shuling Cheng noted that although GLP-1 drugs are highly effective, their appetite-suppressing mechanism often leads to multiple side effects. As a result, global pharmaceutical companies are focusing on new therapies that can be combined with GLP-1 to enhance efficacy while reducing toxicity.
Cheng explained that SNS851 accelerates fat metabolism through a mechanism complementary to GLP-1. When used in combination with a half dose of GLP-1, it not only delivers a significant fat reduction but also improves the lean-to-fat mass ratio, resulting in a “lean body” outcome. Current plans call for a once-monthly intramuscular injection regimen.
The company also shared updates on its wound-care drug and medical device, which are advancing toward commercialization in multiple regions worldwide, including negotiations for commercial collaborations and insurance reimbursement. Cheng emphasized that with 33 published papers and conference presentations, clinical evidence supporting the value of Oneness Biotech’s products continues to grow. Although this stage is often the most challenging for bringing innovative medical products to market, positive feedback from global key opinion leaders and experts is building a strong foundation for business expansion and reimbursement approvals.
Oneness Biotech founder Kong Ming Lu highlighted that the global wound-care market is valued at USD 300 billion, with the United States accounting for half. Yet over 90% of wound treatments still rely on traditional medical care, with no effective new drugs available. Most current options, such as dressings or artificial dermis, are either costly or provide limited efficacy, leading to persistently high amputation rates. Lu said that the company’s wound-care drug and medical device ON101 is poised to address this significant unmet need.
Lu underscored his confidence in ON101’s market potential: “Our goal is to achieve USD 10 billion in sales. This is not just a dream. While it won’t happen overnight, we are confident in making strong, steady progress toward this target.”
Resource: 合一減重藥數據亮眼 第4季臨床試驗
